Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

Rebecca S. Heist,Edward B. Garon,Daniel Shao-Weng Tan,Harry J.M. Groen,Takashi Seto,Egbert F. Smit,Mike R. Zou,Yiqun Yang,Ying Li,Andrea Chassot-Agostinho,Juergen Wolf

Journal of Clinical Oncology（2021）

引用 2|浏览4

暂无评分

摘要

9111Background: Capmatinib, a highly selective and potent MET inhibitor, was approved for patients (pts) with advanced MET exon 14 skipping mutation (METex14) NSCLC in the US and Japan, with the Fo...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要